Martingale Asset Management L P decreased its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 6.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 63,784 shares of the company's stock after selling 4,739 shares during the period. Martingale Asset Management L P's holdings in Cencora were worth $14,331,000 at the end of the most recent reporting period.
A number of other large investors also recently bought and sold shares of COR. JFS Wealth Advisors LLC raised its position in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after buying an additional 46 shares during the period. SBI Securities Co. Ltd. purchased a new position in shares of Cencora in the 4th quarter worth about $30,000. Householder Group Estate & Retirement Specialist LLC lifted its stake in shares of Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after purchasing an additional 69 shares in the last quarter. Kentucky Trust Co purchased a new stake in shares of Cencora during the 4th quarter worth about $33,000. Finally, WASHINGTON TRUST Co increased its position in Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after purchasing an additional 46 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.
Insider Transactions at Cencora
In related news, Chairman Steven H. Collis sold 14,578 shares of the stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the sale, the chairman now owns 317,913 shares in the company, valued at $85,680,732.63. This represents a 4.38 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the completion of the transaction, the executive vice president now owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,675 shares of company stock worth $8,034,778. 10.80% of the stock is currently owned by insiders.
Cencora Stock Down 0.1 %
Shares of COR stock traded down $0.30 during trading hours on Tuesday, hitting $283.99. 268,842 shares of the company were exchanged, compared to its average volume of 1,503,333. The stock has a market capitalization of $55.07 billion, a price-to-earnings ratio of 40.40, a P/E/G ratio of 1.31 and a beta of 0.55. Cencora, Inc. has a one year low of $214.77 and a one year high of $296.65. The business's 50-day simple moving average is $260.88 and its two-hundred day simple moving average is $245.57. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92.
Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Sell-side analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.
Cencora Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.77%. Cencora's payout ratio is 31.29%.
Analysts Set New Price Targets
Several equities research analysts have recently issued reports on COR shares. Wells Fargo & Company increased their price objective on shares of Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Evercore ISI increased their price target on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. JPMorgan Chase & Co. boosted their price objective on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, Bank of America boosted their price target on Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $284.20.
Check Out Our Latest Analysis on COR
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Articles
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
